 Alector Inc NASDAQ: ALEC detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimers Association International Conference AAIC 2021 Patients with one type of frontotemporal dementia decline because theyre missing one copy of an immune-regulating gene called progranulin and subsequently have half the amount of the protein healthy adults have. 